At the 2025 American Society of Hematology (ASH) Annual Meeting, Senior journalist Peter Goodwin from Audio Journal of Oncology invited Professor Du Juan from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine for an on-site interview regarding her team’s research: "FasTCAR-T (GC012F/AZD0120) targeting both BCMA and CD19 as a first-line treatment for newly diagnosed multiple myeloma (NDMM)."

Recently, the international hematology journal Blood Advances published a prospective clinical study by Lu Daopei Medical Team, titled "Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma," reporting breakthrough clinical results of BCMA-targeted nanobody-based CAR-T cell therapy in heavily pretreated refractory/relapsed plasma cell neoplasms.